Business Standard

No rerating yet for diagnostic players despite price hikes as margins fall

While discounts have come down, pricing gap still large between incumbents and new players

pharma
Premium

Ram Prasad Sahu
After December quarter results, which were a mixed bag, and muted near term outlook of listed diagnostics players, brokerages have cut their estimates for FY24. They expect volumes and realisations to be under pressure given weakness in Covid-adjusted test volumes and higher competitive pressures.

In a post Q3 results note on Dr Lal, Bhavesh Gandhi of YES Securities pointed out that there has been a lack of volume revival in recent quarters with an increasing likelihood that FY24 too, would be a work-in-progress year for the company’s initiatives to bear fruit. They have reduced volume growth to mid-single digits next

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 23 2023 | 9:47 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com